Targeting BRD4: Potential therapeutic strategy for head and neck squamous cell carcinoma (Review)

Abstract

As a member of BET (bromodomain and extra-terminal) protein family, BRD4 (bromodomain-containing protein 4) is a chromatin-associated protein that interacts with acetylated histones and actively recruits regulatory proteins, leading to the modulation of gene expression and chromatin remodeling. The cellular and epigenetic functions of BRD4 implicate normal development, fibrosis and inflammation. BRD4 has been suggested as a potential therapeutic target as it is often overexpressed and plays a critical role in regulating gene expression programs that drive tumor cell proliferation, survival, migration and drug resistance. To address the roles of BRD4 in cancer, several drugs that specifically target BRD4 have been developed. Inhibition of BRD4 has shown promising results in preclinical models, with several BRD4 inhibitors undergoing clinical trials for the treatment of various cancers. Head and neck squamous cell carcinoma (HNSCC), a heterogeneous group of cancers, remains a health challenge with a high incidence rate and poor prognosis. Conventional therapies for HNSCC often cause adverse effects to the patients. Targeting BRD4, therefore, represents a promising strategy to sensitize HNSCC to chemo- and radiotherapy allowing de-intensification of the current therapeutic regime and subsequent reduced side effects. However, further studies are required to fully understand the underlying mechanisms of action of BRD4 in HNSCC in order to determine the optimal dosing and administration of BRD4-targeted drugs for the treatment of patients with HNSCC.

Histone modifications in head and neck squamous cell carcinoma

“…Globally, there are more than 600,000 new cases diagnosed each year, with a higher incidence in regions such as Southeast Asia and Central Europe. Characterized by high heterogeneity and mortality rate, about 60% of patients are already in the advanced stage when they seek medical help ( 1 ). It is well-known that genetic and epigenetic alterations are the main hallmarks of HNSCC tumorigenesis ( Figure 1 ).…”